EUVIMEDEUVIMED entdecken
Vergleichsstudie

Preclinical Evaluation of Effects of KP-001, a Selective Phosphatidylinositol 3-Kinase Alpha (PI3Kα) Inhibitor, on Human Immune Cell Function in Comparison with Existing Drugs for Refractory Vascular Malformations

Daiki Kato, Erika Koyama

Biological and Pharmaceutical Bulletin · 12.11.2026 · 49 (11) · 1866-1872

DOI: 10.1248/bpb.b26-00312 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Biological and Pharmaceutical Bulletin, erschienen am 12.11.2026. Verfasst von Daiki Kato und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 14, Shinomiya Minamigawara-cho, Yamashina-ku, Kyoto 607-8042, Japan. Hauptthemen laut MEDLINE: Phosphoinositide-3 Kinase Inhibitors, Class I Phosphatidylinositol 3-Kinases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphoinositide-3 Kinase InhibitorsClass I Phosphatidylinositol 3-KinasesHumansSirolimusT-LymphocytesThiazolesB-Lymphocytes

Stichwörter der Autor:innen

KP-001alpelisibimmunosuppressionphosphatidylinositol 3-kinase alpha (PI3Kα)sirolimusvascular malformation

Substanzen

SirolimusPhosphoinositide-3 Kinase InhibitorsClass I Phosphatidylinositol 3-KinasesAlpelisibThiazoles

Autor:innen und Institutionen

  • Pharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 14, Shinomiya Minamigawara-cho, Yamashina-ku, Kyoto 607-8042, Japan.

Zitieren

APA

Kato, D., & Koyama, E. (2026). Preclinical Evaluation of Effects of KP-001, a Selective Phosphatidylinositol 3-Kinase Alpha (PI3Kα) Inhibitor, on Human Immune Cell Function in Comparison with Existing Drugs for Refractory Vascular Malformations. Biological and Pharmaceutical Bulletin, 49(11), 1866-1872. https://doi.org/10.1248/bpb.b26-00312

Vancouver

Kato D, Koyama E. Preclinical Evaluation of Effects of KP-001, a Selective Phosphatidylinositol 3-Kinase Alpha (PI3Kα) Inhibitor, on Human Immune Cell Function in Comparison with Existing Drugs for Refractory Vascular Malformations. Biological and Pharmaceutical Bulletin. 2026;49(11):1866-1872. doi:10.1248/bpb.b26-00312

BibTeX
@article{Kato2026,
  author = {Kato, Daiki and Koyama, Erika},
  title = {Preclinical Evaluation of Effects of KP-001, a Selective Phosphatidylinositol 3-Kinase Alpha (PI3Kα) Inhibitor, on Human Immune Cell Function in Comparison with Existing Drugs for Refractory Vascular Malformations},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2026},
  volume = {49},
  number = {11},
  pages = {1866--1872},
  doi = {10.1248/bpb.b26-00312}
}
Kostenlos starten →